Malaria Segment Bolsters Nigeria Infectious Disease In-vitro Diagnostics Market Growth
According to our new research study on "Nigeria Infectious Disease In-vitro Diagnostics Market Forecast to 2031 – Country Analysis – by Application and End User," the market was valued at US$ 41.04 million in 2024 and is projected to reach US$ 59.67 million by 2031; it is estimated to register a CAGR of 5.5% during 2024–2031. The Nigeria Infectious Disease In-vitro Diagnostics Market report emphasizes the trends prevalent in the market, along with drivers and deterrents affecting its growth.
An increase in the number of diagnostic centers and strategic developments by key players contribute to the growing Nigeria Infectious Disease In-vitro Diagnostics Market size. However, the lack of skilled laboratory professionals hampers the market growth. Further, the technological advancementis expected to bring new Nigeria Infectious Disease In-vitro Diagnostics Market trends in the coming years.
Nigeria Infectious Disease In-vitro Diagnostics Market Share, by Application, 2024 (%)
Nigeria Infectious Disease In-vitro Diagnostics Market Size and Forecast (2021 - 2031), Country Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application (HIV/AIDS, Tuberculosis, Hepatitis B & C, Malaria, and Others), End User (Hospitals and Clinics, Diagnostic Laboratories, Blood Bank, and Others), and Geography
Nigeria Infectious Disease In-vitro Diagnostics Market Size 2031
Download Free Sample
Source: The Insight Partners Analysis
Increasing Number of Diagnostic Center Fuels Nigeria Infectious Disease In-vitro Diagnostics Market Growth
As of May 2025, there are 937 Diagnostic centers in Nigeria, representing a 3.65% increase from 2023. Of these locations, 899 Diagnostic centers, which is 95.94% of all Diagnostic centers in Nigeria, are single-owner operations, while the remaining 38, 4.06%, are part of larger brands. The top three states with the most diagnostic centers are Lagos, with 256 Diagnostic centers; Federal Capital Territory, with 104 Diagnostic centers; and Enugu State, with 72 Diagnostic centers.
With the rising burden of infectious diseases such as malaria, HIV, and tuberculosis, the demand for accurate and timely diagnostic services is surging. The increased availability of diagnostic centers, particularly in urban and semi-urban areas, has improved healthcare accessibility and reduced patient turnaround times, thereby boosting the adoption of IVD technologies. Establishing private labs such as 54gene and Lifebank and public initiatives under the Nigeria Centre for Disease Control (NCDC) has increased testing capacity for COVID-19 and Lassa fever. These centers rely on molecular diagnostics, immunoassays, and rapid test kits. Collaborations with international partners have led to capacity-building and technology transfer. Expansion of diagnostic capabilities improves accurate diagnosis, disease monitoring, supporting public health responses, and shaping healthcare policies—all of which contribute to the Nigeria Infectious Disease In-vitro Diagnostics Market Growth.
The Nigeria Infectious Disease In-vitro Diagnostics Market analysis has been carried out by considering the following segments: application, end user, and geography. Based on application, the Nigeria infectious disease in-vitro diagnostics market is divided into HIV/AIDS, tuberculosis, hepatitis b & c, malaria, and others. Malaria held the major Nigeria infectious disease in-vitro diagnostics market share in 2024. According to the World Health Organization’s World Malaria Report 2023, Nigeria accounts for approximately 27% of global malaria cases and 31% of malaria-related deaths, making it the most malaria-endemic country in Africa. In 2022, the government reported an estimated 66.7 million malaria cases, with severe malaria leading to 189,321 deaths, predominantly among children under five. This high prevalence has driven the demand for reliable and accessible diagnostic solutions, which are crucial for early detection and appropriate treatment.
By end user, the market is segmented into hospitals and clinics, diagnostic laboratories, blood banks, and others. Hospitals and clinics held the major Nigeria Infectious Disease In-vitro Diagnostics Market share in 2024. The need for accurate, timely diagnosis in hospitals and clinics is rising steadily due to frequent outbreaks of Lassa fever, cholera, tuberculosis, and malaria. The soaring patient load and demand for quality care have pushed hospitals to adopt more sophisticated diagnostic tools, including molecular diagnostics. Increased government funding, donor support, and infrastructure improvements in secondary and tertiary hospitals further boost the adoption of IVD products. Integrating IVD in hospital protocols improves patient outcomes, reduces unnecessary antibiotic use, and ensures better management of infectious diseases in urban and rural health centers.
The geographic scope of the Nigeria Infectious Disease In-vitro Diagnostics Market report includes the assessment of the market performance in Nigeria.
The industry landscape chapter briefly explains the various product developments, partnerships, mergers and acquisitions, and collaboration strategies implemented by the companies. With all these strategies, the companies enhance their product offerings and footprint across all industries, therefore boosting the annual revenue growth. The market initiative is a strategy adopted by companies to expand their footprint worldwide and to meet the growing customer demand. The market players present in the Nigeria Infectious Disease In-vitro Diagnostics Market are focusing on product and service enhancements by integrating advanced features and technologies into their offerings.
The market players focus on mergers & acquisitions to achieve sustainable growth and to distinguish themselves among competitors present in the highly competitive Nigeria Infectious Disease In-vitro Diagnostics Market. In January 2024, Roche entered into a definitive agreement to acquire LumiraDx’s point-of-care technology, combining multiple diagnostic modalities on a single platform. This acquisition will complement Roche's existing diagnostics portfolio, offering multiple point-of-care tests on a simple instrument for affordable and accessible testing worldwide. The purchase price is US$ 295 million, with an additional payment of up to US$ 55 million.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com